Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
22 Cards in this Set
- Front
- Back
What are some etiologies of leukemia? (5)
|
1) chemical exposure (benzene)
2) radiation therapy 3) chemo therapy* 4) inherited genetic instability (Down's) 5) transforming virus * major cause nowadays |
|
AML cytogenetics ~
M2 = t(___:___) M3 = t(___:___) M4 = inversion ___ Biphenotypic AML = t(___:___) |
8:21
15:17 16 4:11 |
|
How does AML present clinically?
|
1) DIC
2) leukostasis (>75000 blasts) 3) hyperuricemia 4) hepatosplenomegaly 5) pancytopenia 6) "tumor lysis syndrome" |
|
What are some good cytogenetic prognostic factors for AML?
|
inversion 16, t(15;17), t(8;21)
|
|
What are some bad prognostic factors for AML?
(age, WBC count, etc.) |
> 60 yrs
high WBC count prior Myelodysplastic Syndrome prior chemo therapy |
|
What is consolidation therapy for AML?
|
HIGH dose cytarabine
(tox: leukopenia, thrombocytopenia, megaloblastic anemia) |
|
What is used in targeted therapy for AML?
|
anti-CD33, because young cells have CD33
|
|
Acute Promyelocytic Leukemia (M3 AML) responds to _____ & _____ therapy.
|
all trans retinoic acid
arsenic |
|
What stain can differentiate between lymphoid blasts and myeloblasts?
|
PAS - lymphoid blasts have glycogen
|
|
Pre-B lymphoblsts are positive for _____ & _____.
|
TDT & CD10 (CALLA)
|
|
ALL affects mostly _____.
|
children (30% of childhood leukemias)
|
|
ALL has higher incidence of tumor spread to _____ & _____.
|
CNS, testes
|
|
Treatment of ALL includes:
|
induction
consolidation maintenance CNS prophylaxis (intrathecal) allogeneic transplant |
|
Cytogenetic abnormality in CML:
|
t(9:22) --> bcr-abl chimeric protein --> super pluripotent stem cell --> become either lymphoid or myeloid cells
|
|
CML clinical features:
|
1) no sxs in early stage, just high WBC
2) rising WBC in all stages 3) low neutrophilic ALP 4) accelerated phase - anemia, thrombocytopenia, but basophilia and fibrosis |
|
CLL expresses which surface protein marker?
|
CD5
|
|
CLL typically occurs in which gender and age population?
|
Men > 50 yrs
|
|
Clinicaly features of CLL:
|
1) hypogammaglobulinemia
2) inc. infections 3) T-cell dysregulation 4) second malignancy 5) autoimmunity (hemolytic anemia) |
|
Indications for initiating therapy in CLL:
|
massive LNs and spleen
|
|
CLL Tx:
|
1) alkylater therapy (chlorambucil, cytoxan)
2) purine analog (fludarabine) 3) rituximab, campath |
|
MDS definition:
|
Absence of pluripotent progenitors.
|
|
MDS presentation:
|
inc. incidence with age, progressive pancytopenia, macrocytosis, poikilocytosis, anisocytosis
|